About Hervolution
Hervolution is a company based in Copenhagen (Denmark) founded in 2018. Hervolution has raised $18.17 million across 2 funding rounds from investors including Serum Institute of India, European Union and EIC Fund. The company has 13 employees as of November 30, 2024. Hervolution offers products and services including Immunotherapy Platform and Pipeline Assets. Hervolution operates in a competitive market with competitors including Ardelyx, VBI Vaccines, HilleVax, DermBiont and Inozyme Pharma, among others.
- Headquarter Copenhagen, Denmark
- Employees 13 as on 30 Nov, 2024
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Inprother Aps
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$18.17 M (USD)
in 2 rounds
-
Latest Funding Round
$11.7 M (USD), Series A
Dec 19, 2024
-
Investors
Serum Institute of India
& 2 more
-
Employee Count
13
as on Nov 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hervolution
Hervolution offers a comprehensive portfolio of products and services, including Immunotherapy Platform and Pipeline Assets.
Engineers therapies targeting HERVs for disease treatment.
Off-the-shelf assets for cancer and metabolic disease interventions.
Funding Insights of Hervolution
Hervolution has successfully raised a total of $18.17M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $11.7 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hervolution
Hervolution has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Serum Institute of India, European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Hervolution
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hervolution
Investment portfolio details for Hervolution
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Hervolution
Detailed financials for Hervolution
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hervolution Comparisons
Peer comparison for Hervolution
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hervolution
Hervolution operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ardelyx, VBI Vaccines, HilleVax, DermBiont and Inozyme Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
VBI Vaccines is engaged in developing vaccines and immunotherapeutics.
|
|
| Locked | Locked | Locked |
A norovirus vaccine is developed for infection prevention.
|
|
| Locked | Locked | Locked |
Microbial therapeutics for skin diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of treatments for rare and debilitating metabolic diseases
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases, including antigens and adjuvants, were developed.
|
Detailed competitors of Hervolution
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hervolution
Complete news archive for Hervolution
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hervolution
Hervolution was founded in 2018 and raised its 1st funding round 5 years after it was founded.
Hervolution is headquartered in Copenhagen, Denmark.
Hervolution is a funded company, having raised a total of $18.17M across 2 funding rounds to date.
As of Nov 30, 2024, the latest employee count at Hervolution is 13.
Hervolution was founded in 2018 and is headquartered in Copenhagen, Denmark. Focus is placed on the biotechnology sector, where immunotherapies for cancer treatment are developed. A lead candidate, IPT001, is advanced as a vaccine that employs Adenoviral and RNA vectors. Human Endogenous Retroviruses are targeted as antigens specific to tumors and senescence. Operations involve research into oncology solutions through endogenous viral elements.
Hervolution's top competitors include Ardelyx, HilleVax and VBI Vaccines.
Hervolution offers Immunotherapy Platform and Pipeline Assets.
Hervolution has 3 investors. Key investors include Serum Institute of India, European Union, and EIC Fund.